Rolf Müller and Katharina Schaufler Portrait collage
© HIPS/Bernhardt; HIOH/Wally Pruß
Rolf Müller and Katharina Schaufler have been appointed to the Scientific Advisory Board of the European Partnership on One Health Antimicrobial Resistance.
News

International Consortium Against Antimicrobial Resistance

Rolf Müller and Katharina Schaufler become members of the scientific advisory board of the European partnership OHAMR

Two researchers from the Helmholtz Centre for Infection Research (HZI) serve as advisors to a European consortium working to combat antimicrobial resistance. Prof. Rolf Müller, Scientific Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Head of the Research Unit “Novel Antibiotics” at the German Center for Infection Research (DZIF), and Prof. Katharina Schaufler, Head of the Department “Epidemiology and ecology of antimicrobial resistance” at the Helmholtz Institute for One Health, have been appointed to the Scientific Advisory Board of the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR). HIPS and HIOH are sites of the HZI in collaboration with Saarland University and partner institutions in Greifswald, respectively.

Founded in 2025 and co-financed by the European Commission, the consortium is expected to provide around €250 million in funding for research and innovation projects in the field of antimicrobial resistance over the next ten years. In addition, EUP OHAMR will focus on capacity strengthening, better exploitation of research data, and the translation of basic research findings into potential applications. In the long term, the initiative aims to contribute to the development of new solutions for the treatment and prevention of resistant infections and to close existing knowledge gaps on the topic of AMR. EUP OHAMR thus directly follows up on the activities of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), which ended in May 2025.

As members of the Scientific Advisory Board, Müller and Schaufler will advise EUP OHAMR on scientific and strategic issues related to the topic of “One Health.” In addition, the 16 members of the Advisory Board will provide feedback from the scientific community and be available for workshops and networking activities. All members will initially be appointed for a period of three years, with the possibility of a one-time extension.

Further information

Scientific advisory board of the European partnership OHAMR

[Translate to English:] Charlotte Schwenner

Press contact

Dr Charlotte Schwenner
Science Editor
+49 531 6181-1406

Research Groups

Locations

Related News

Fluorescence microscopy of cells in magenta and blue
News

New platform for the production of versatile active ingredients

Natural products derived from microorganisms are a promising source of new active ingredients, but are often produced only in very small quantities. A research team from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) led by Tobias Gulder has now succeeded in establishing a chemo-enzymatic platform for the production of furanolides – a class of natural products with a broad spectrum of activity. This strategy not only allows furanolides to be produced cost-effectively, but also enables structural modifications to be made. The newly generated molecules are capable of effectively combating both bacterial pathogens and cancer cells. The team has now published its findings in the Journal of the American Chemical Society.
Rolf Müller
News

Mannich Medal for Rolf Müller

Professor Rolf Müller, Scientific Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Professor of Pharmaceutical Biology at Saarland University, has been awarded the Mannich Medal by the German Pharmaceutical Society (DPhG). Awarded in honour of the German chemist Carl Mannich, the medal is the DPhG's highest scientific accolade and is presented annually for “outstanding achievements in the field of pharmaceutical sciences”. The medal was presented at the DPhG's annual conference in Freiburg on October 1, 2025. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University.
NMR
News

Scientists discover first „Saar-drug“

New, resistance-breaking drugs are urgently needed to effectively treat infections with antibiotic-resistant germs in the future. Researchers from Saarbrücken and Vienna have now found a possible starting point for the development of such drugs in the natural product Saarvienin A. This novel molecule is capable of killing bacteria even if they are already resistant to clinically used antibiotics. The researchers published their findings in the journal Angewandte Chemie International Edition.